Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7566802 alone and with Atezolizumab in advanced solid tumors
NCT06031441Phase 1Active, not recruiting
- Sponsor
- Genentech
- Start
- Nov 2023
- Primary completion
- Mar 2028
- Modality
- Biologic
- Countries
- 5
01
Overview
Phase 1, open-label trial of RO7566802 in solid tumor (2 cohorts), sponsored by Genentech. Primary endpoints: Number of Participants with Dose-limiting Toxicity at 42 days and Percentage of Participants with Adverse Events at 4 years. Started Nov 2023; status: active, not recruiting.
02
Drugs
RO7566802
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06031441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06031441.